Skip to content

A randomized controlled study of atomized inhalation plasma-activated water loading standard regimen in the treatment of COVID-19

A randomized controlled study of atomized inhalation plasma-activated water loading standard regimen in the treatment of COVID-19

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2300078705
Enrollment
Unknown
Registered
2023-12-15
Start date
2023-05-24
Completion date
Unknown
Last updated
2023-12-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

COVID-19

Interventions

Sponsors

The First Affiliated Hospital of Air Force Military Medical University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 85 Years

Inclusion criteria

Inclusion criteria: 1.18-85years old (including18and85years old), regardless of gender. 2.COVID-19-related symptoms such as fever and cough occurred within 2 weeks of onset. 3.After the onset of the disease, the subjects were positive for SARS-CoV-2 nucleic acid or antigen in sputum / nasal swabs / pharynx swabs / lower respiratory tract secretions. Diagnosed as COVID-19. 4. Meet the diagnostic criteria of moderate and severe patients in the latest version of COVID-19 Diagnosis and Treatment Program (10th Edition) issued by the China Health Commission. 5. Did not receive antiviral treatment before entering the group. 6. Understand and sign the informed consent form.

Exclusion criteria

Exclusion criteria: 1.Critical COVID-19 patients meet any of the following criteria:(1) respiratory failure and need mechanical ventilation;(2) shock;(3) ICU monitoring and treatment for patients with other organ failure. 2.Hyperallergenic constitution, including allergic bronchial asthma, etc. 3.Suspected or confirmed presence of bacteria, fungi, atypical pathogens and other pathogens in the lungs. 4.Pregnant or lactating women or those with positive pregnancy test, or those who plan to conceive within half a year. 5.There are basic pulmonary diseases that significantly affect the observation of pulmonary imaging (such as bronchiectasis, interstitial lung disease, pneumoconiosis). 6. The researchers believe that other factors that are not suitable for entering the trial, such as difficulties in communication, severe neurological and mental disorders, and severe physical weakness.

Design outcomes

Primary

MeasureTime frame
Improvement rate of chest imaging;

Secondary

MeasureTime frame
The rate of negative SARS-CoV-2 nucleic acid test or Ct value;Quantitative score of symptoms (fatigue, shortness of breath, cough, expectoration),signs;Inflammatory factors, blood routine;The rate of aggravation of COVID-19 clinical classification(moderate aggravated to severe,severe aggravated to critical);

Countries

China

Contacts

Public ContactLiqiang Song

The First Affiliated Hospital of the Air Force Military Medical University

songlq@fmmu.edu.cn+86 139 9116 0546

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026